JP7245229B2 - ベンゾスルホニル化合物 - Google Patents

ベンゾスルホニル化合物 Download PDF

Info

Publication number
JP7245229B2
JP7245229B2 JP2020510091A JP2020510091A JP7245229B2 JP 7245229 B2 JP7245229 B2 JP 7245229B2 JP 2020510091 A JP2020510091 A JP 2020510091A JP 2020510091 A JP2020510091 A JP 2020510091A JP 7245229 B2 JP7245229 B2 JP 7245229B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020510091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533280A (ja
JP2020533280A5 (enExample
Inventor
ダブリュー． コンラディ，アンドレイ
ズ－リン タン リン，トレーシー
Original Assignee
ビバーチェ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビバーチェ セラピューティクス，インク． filed Critical ビバーチェ セラピューティクス，インク．
Publication of JP2020533280A publication Critical patent/JP2020533280A/ja
Publication of JP2020533280A5 publication Critical patent/JP2020533280A5/ja
Application granted granted Critical
Publication of JP7245229B2 publication Critical patent/JP7245229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2020510091A 2017-08-21 2018-08-20 ベンゾスルホニル化合物 Active JP7245229B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548037P 2017-08-21 2017-08-21
US62/548,037 2017-08-21
PCT/US2018/047112 WO2019040380A1 (en) 2017-08-21 2018-08-20 BENZOSULFONYL COMPOUNDS

Publications (3)

Publication Number Publication Date
JP2020533280A JP2020533280A (ja) 2020-11-19
JP2020533280A5 JP2020533280A5 (enExample) 2021-09-30
JP7245229B2 true JP7245229B2 (ja) 2023-03-23

Family

ID=65439937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020510091A Active JP7245229B2 (ja) 2017-08-21 2018-08-20 ベンゾスルホニル化合物

Country Status (7)

Country Link
US (1) US11192865B2 (enExample)
EP (1) EP3691623B1 (enExample)
JP (1) JP7245229B2 (enExample)
CN (1) CN111542315B (enExample)
AU (1) AU2018321291A1 (enExample)
CA (1) CA3073543A1 (enExample)
WO (1) WO2019040380A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
EP3691623B1 (en) 2017-08-21 2022-10-05 Vivace Therapeutics, Inc. Benzosulfonyl compounds
EP3720430A4 (en) 2017-12-06 2021-05-05 Vivace Therapeutics, Inc. BENZOCARBONYL COMPOUNDS
US11661403B2 (en) 2018-05-16 2023-05-30 Vivace Therapeutics, Inc. Oxadiazole compounds
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
MX2021014443A (es) * 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
US11458149B1 (en) * 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
EP4003983A1 (en) 2019-07-29 2022-06-01 Basilea Pharmaceutica International AG 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
CN115279368B (zh) * 2019-11-20 2024-05-24 维瓦斯治疗公司 杂芳基化合物
US20230192607A1 (en) * 2019-12-24 2023-06-22 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
CN115515959A (zh) * 2020-05-08 2022-12-23 默克专利股份公司 用作tead结合剂的三环杂环
CA3180846A1 (en) * 2020-06-03 2021-12-09 Dana-Farber Cancer Institute, Inc. Inhibitors of transcriptional enhanced associate domain (tead) and uses thereof
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
PE20240017A1 (es) 2020-09-30 2024-01-04 Univ Leuven Kath Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
WO2022120353A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2022210800A1 (en) 2021-01-25 2023-08-10 Ikena Oncology, Inc. Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
US20240083903A1 (en) * 2021-02-18 2024-03-14 Merck Sharp & Dohme Llc Aryl ether compounds as tead modulators
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
JP2024519845A (ja) * 2021-05-19 2024-05-21 ジェネンテック， インコーポレイテッド 併用療法
WO2022258040A1 (zh) * 2021-06-11 2022-12-15 武汉人福创新药物研发中心有限公司 用于tead抑制剂的杂环化合物
CN115594680A (zh) * 2021-07-07 2023-01-13 武汉人福创新药物研发中心有限公司（Cn） 一种tead抑制剂
AU2022336415A1 (en) 2021-09-01 2024-01-04 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
US20240279191A1 (en) * 2021-09-24 2024-08-22 The General Hospital Corporation Small molecule inhibitors of tead-yap
WO2023057371A1 (en) 2021-10-04 2023-04-13 Basilea Pharmaceutica International Ag, Allschwil 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
WO2023060227A1 (en) 2021-10-07 2023-04-13 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2022417524A1 (en) 2021-12-23 2024-08-01 Katholieke Universiteit Leuven 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead
WO2023116877A1 (zh) * 2021-12-24 2023-06-29 武汉人福创新药物研发中心有限公司 作为tead抑制剂的杂环化合物
CN118715221A (zh) * 2022-01-30 2024-09-27 希格生科（深圳）有限公司 三环化合物及其应用
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023204822A1 (en) * 2022-04-22 2023-10-26 Vivace Therapeutics, Inc. Phenyl phosphine oxide compounds and methods of use thereof
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途
WO2024061366A1 (zh) * 2022-09-23 2024-03-28 杭州天玑济世生物科技有限公司 具有磷酰化芳基结构的小分子化合物及其应用
TW202423428A (zh) 2022-09-29 2024-06-16 香港商英矽智能科技知識產權有限公司 Tead抑制劑及其使用方法
CN120019051A (zh) 2022-10-13 2025-05-16 韩美药品株式会社 用于抑制yap-tead交互作用的新颖杂双环化合物及包含其的药学组成物
TW202417429A (zh) * 2022-10-13 2024-05-01 南韓商韓美藥品股份有限公司 用於抑制yap-tead交互作用的新穎雜雙環化合物及包含其之藥學組成物
WO2024092116A1 (en) 2022-10-26 2024-05-02 Ikena Oncology, Inc. Combination of tead inhibitors and egfr inhibitors and uses thereof
EP4596561A1 (en) 2022-10-27 2025-08-06 Suzhou Genhouse Bio Co., Ltd. Phosphorus-containing compound, pharmaceutical composition and use thereof
WO2024099435A1 (zh) * 2022-11-10 2024-05-16 武汉人福创新药物研发中心有限公司 Tead抑制剂
AU2023380159A1 (en) 2022-11-18 2025-05-15 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024173761A1 (en) 2023-02-17 2024-08-22 Ikena Oncology, Inc. Combinations comprising mek inhibitors for use in the treatment of cancer
EP4669320A1 (en) 2023-02-23 2025-12-31 Novartis AG COMBINATIONS OF TEAD AND KRAS G12D INHIBITORS FOR CANCER TREATMENT
CN120676942A (zh) 2023-02-23 2025-09-19 诺华股份有限公司 用于治疗癌症的tead抑制剂和her2抑制剂组合
KR20250097400A (ko) 2023-12-21 2025-06-30 한미약품 주식회사 Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523354A (ja) 2012-06-12 2015-08-13 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
JP2015531787A (ja) 2012-09-13 2015-11-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 卵胞の発達及び卵母細胞の成熟の刺激
JP2016512542A (ja) 2013-03-12 2016-04-28 アッヴィ・インコーポレイテッド ピロールアミド阻害剤
JP2016533397A (ja) 2013-10-18 2016-10-27 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895027A (en) 1974-04-12 1975-07-15 Lilly Co Eli Process for preparing pyrazole-3-carboxylic acids
US3903106A (en) 1974-04-12 1975-09-02 Lilly Co Eli Pyrazole-3-carboxylic acids
DE2419970C3 (de) 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DE2917997A1 (de) * 1979-05-04 1980-11-20 Hoechst Ag Substituierte pyrrolidinyl-benzoesaeure- derivate und verfahren zu ihrer herstellung
JP2630432B2 (ja) 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
US5066668A (en) 1989-06-09 1991-11-19 Warner-Lambert Co. Triazole derivatives of fenamates as antiinflammatory agents
US4962119A (en) 1989-06-09 1990-10-09 Warner-Lambert Company Triazole derivatives of fenamates as antiinflammatory agents
FI902771A7 (fi) 1989-06-09 1990-12-10 Warner Lambert Co Menetelmä anti-inflammatoristen 1,3,4-tiadiatsolien ja 1,3,4-oksadiatsolien valmistamiseksi
US5114958A (en) 1991-05-09 1992-05-19 Warner-Lambert Company 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents
US5670526A (en) 1995-12-21 1997-09-23 Otsuka Pharmaceutical Co., Ltd. 1,3,4-oxadiazoles
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6211209B1 (en) 1997-08-08 2001-04-03 Warner-Lambert Company Method of inhibiting connective tissue degradation
IL144215A0 (en) 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
AU5785900A (en) 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
WO2006045514A1 (en) 2004-10-20 2006-05-04 Applied Research Systems Ars Holding N.V. 3-arylamino pyridine derivatives
US8097650B2 (en) 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1
ZA200807263B (en) 2006-04-19 2009-11-25 Serono Lab Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
TWI557127B (zh) 2009-09-04 2016-11-11 百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2858635A1 (en) 2012-06-11 2015-04-15 The Regents of The University of California Inhibitors of hippo-yap signaling pathway
US9994577B2 (en) 2014-07-04 2018-06-12 Merck Patent Gmbh Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity
MX2017012729A (es) 2015-04-03 2017-11-15 Bristol Myers Squibb Co Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
WO2017058716A1 (en) * 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
EP3156404A1 (en) * 2015-10-15 2017-04-19 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
EP3691623B1 (en) 2017-08-21 2022-10-05 Vivace Therapeutics, Inc. Benzosulfonyl compounds
EP3720430A4 (en) 2017-12-06 2021-05-05 Vivace Therapeutics, Inc. BENZOCARBONYL COMPOUNDS
US11661403B2 (en) 2018-05-16 2023-05-30 Vivace Therapeutics, Inc. Oxadiazole compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523354A (ja) 2012-06-12 2015-08-13 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
JP2015531787A (ja) 2012-09-13 2015-11-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 卵胞の発達及び卵母細胞の成熟の刺激
JP2016512542A (ja) 2013-03-12 2016-04-28 アッヴィ・インコーポレイテッド ピロールアミド阻害剤
JP2016533397A (ja) 2013-10-18 2016-10-27 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤

Also Published As

Publication number Publication date
EP3691623B1 (en) 2022-10-05
EP3691623A1 (en) 2020-08-12
US11192865B2 (en) 2021-12-07
US20200354325A1 (en) 2020-11-12
WO2019040380A1 (en) 2019-02-28
JP2020533280A (ja) 2020-11-19
AU2018321291A1 (en) 2020-03-26
CA3073543A1 (en) 2019-02-28
EP3691623A4 (en) 2021-05-26
CN111542315A (zh) 2020-08-14
CN111542315B (zh) 2023-05-12

Similar Documents

Publication Publication Date Title
JP7245229B2 (ja) ベンゾスルホニル化合物
JP7482861B2 (ja) 二環式化合物
JP7653362B2 (ja) 二環式化合物
US11524943B1 (en) Benzocarbonyl compounds
US11661403B2 (en) Oxadiazole compounds
US11186554B2 (en) Non-fused tricyclic compounds
JP6663866B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
EP4061364A1 (en) Heteroaryl compounds
EA036788B1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2023146513A1 (en) Compounds and methods of use thereof
EA046394B1 (ru) Бициклические соединения
EA047446B1 (ru) Бициклические соединения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230310

R150 Certificate of patent or registration of utility model

Ref document number: 7245229

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150